New Delhi: Glenmark Pharmaceuticals said it has completed phase 3 study of its investigational fixed-dose combination nasal spray and plans to submit a new drug application with the US health regulator. In a BSE filing, Glenmark said it met its primary clinical endpoint in a phase 3 study evaluating the safety of Ryaltris, an investigational fixed-dose combination nasal spray, used to treat seasonal allergic rhinitis. Glenmark plans to "submit the company's first new drug application (NDA) to the USFDA for Ryaltris for the treatment of patients with seasonal allergic rhinitis (SAR) in the first quarter of the calendar year 2018," it added. The company said Ryaltris has been conditionally accepted as the brand name for GSP 301 Nasal Spray by the US Food and Drug Administration (USFDA).